Skip to main content

Table 2 Antimicrobial activity against resistant respiratory Enterobacterales isolates by subset (ATLAS 2016–2018)

From: In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016–2018)

Organism Antimicrobial MIC (mg/L) %S %I %R
MIC90 Range
Enterobacterales,
ESBL-positive (n = 1963)
Amoxicillin-clavulanate ≥64 1–≥64 14.5 N/A 85.5
Piperacillin-tazobactam ≥256 ≤0.25–≥256 40.4 12.5 47.1
Aztreonam ≥256 0.06–≥256 0.7 4.2 95.1
Ceftazidime ≥256 0.25–≥256 2.6 8.2 89.2
Ceftazidime-avibactam 2 ≤0.015–≥256 93.6 N/A 6.4
Cefepime ≥64 ≤0.12–≥64 2.9 7.4 89.8
Imipenem ≥16 ≤0.03–≥16 82.7 4.0 13.3
Meropenem 16 0.015–≥32 84.1 3.3 12.6
Levofloxacin ≥16 ≤0.03–≥16 18.3 12.0 69.7
Colistin (n = 1931)a 1 ≤0.06–≥16 94.6 N/A 5.4
Amikacin 32 ≤0.25–≥128 82.5 N/A 17.5
Tigecyclineb 2 ≤0.015–≥16 98.8 0.0 1.2
Enterobacterales,
ESBL/carbapenemase-
positive (n = 351)
Amoxicillin-clavulanate ≥64 1–≥64 0.6 N/A 99.4
Piperacillin-tazobactam ≥256 0.25–≥256 1.7 0.3 98.0
Aztreonam ≥256 0.12–≥256 1.1 2.0 96.9
Ceftazidime ≥256 0.5–≥256 1.4 1.7 96.9
Ceftazidime-avibactam ≥256 0.03–≥256 64.7 N/A 35.3
Cefepime ≥64 ≤0.12–≥64 1.1 2.6 96.3
Imipenem ≥16 0.25–≥16 16.2 12.0 71.8
Meropenem ≥32 0.03–≥32 18.8 13.7 67.5
Levofloxacin ≥16 0.06–≥16 6.0 4.8 89.2
Colistin (n = 346)a ≥16 ≤0.06–≥16 79.2 N/A 20.8
Amikacin ≥128 0.5–≥128 58.1 N/A 41.9
Tigecyclineb 2 0.06–8 92.9 0.0 7.1
Enterobacterales,
carbapenemase positive/
MBL-negative (n = 362)
Amoxicillin-clavulanate ≥64 1–≥64 0.6 N/A 99.4
Piperacillin-tazobactam ≥256 0.25–≥256 1.1 0.6 98.3
Aztreonam ≥256 0.06–≥256 7.5 1.1 91.4
Ceftazidime ≥256 0.25–≥256 7.5 3.3 89.2
Ceftazidime-avibactam 4 ≤0.015–≥256 98.9 N/A 1.1
Cefepime ≥64 ≤0.12–≥64 6.1 5.8 88.1
Imipenem ≥16 0.25–≥16 19.3 14.6 66.0
Meropenem ≥32 0.03–≥32 21.8 19.3 58.8
Levofloxacin ≥16 0.06–≥16 7.2 5.2 87.6
Colistin (n = 359)a ≥16 ≤0.06–≥16 74.1 N/A 25.9
Amikacin 64 0.5–≥128 59.1 N/A 40.9
Tigecyclineb 2 0.06–8 100 0.0 0.0
Enterobacterales,
MBL-positive (n = 157)c
Amoxicillin-clavulanate ≥64 32–≥64 0.0 N/A 100
Piperacillin-tazobactam ≥256 2–≥256 3.8 0.0 96.2
Aztreonam ≥256 ≤0.015–≥256 10.8 3.8 85.4
Ceftazidime ≥256 32–≥256 0.0 0.0 100
Ceftazidime-avibactam ≥256 16–≥256 0.0 N/A 100
Cefepime ≥64 4–≥64 0.0 1.3 98.7
Imipenem ≥16 1–≥16 7.0 8.3 84.7
Meropenem ≥32 0.25–≥32 10.8 15.9 73.2
Levofloxacin ≥16 0.06–≥16 10.2 3.2 86.6
Colistin (n = 146)a 4 ≤0.06–≥16 89.0 N/A 11.0
Amikacin ≥128 0.5–≥128 42.7 N/A 57.3
Tigecyclineb 2 0.12–8 90.0 0.0 10.0
  1. MIC minimum inhibitory concentration; MIC90 MIC required to inhibit the growth of 90% of isolates; %S percent susceptible, standard dosing regimen; %I percent susceptible, increased exposure; %R percent resistant; N/A not applicable; ESBL extended-spectrum β-lactamase; MBL metallo-β-lactamase
  2. aIsolates of Morganella spp., Proteus spp., Providencia spp. or Serratia spp. were excluded due to intrinsic resistance
  3. bTigecycline EUCAST breakpoints only apply to isolates of Citrobacter koseri and Escherichia coli
  4. cIsolates in this subset are carbapenemase-positive and MBL-positive